A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513 Phase 1/Phase 2 UNKNOWN

Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.

Details

Lead sponsor	Dow Pharmaceutical Sciences
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	60
Start date	2012-06
Completion	2013-07

Conditions

• Plaque Psoriasis

Interventions

• IDP-118 Low Strength
• IDP-118 High Strength

Primary outcomes

• The incidence of HPA axis suppression after treatment with investigational drug product and the comparators — 8 weeks
  To measure the incidence of HPA axis suppression after treatment with investigational drug product and the comparators

Countries

United States